Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In the treatment-policy estimand analysis, at week 26 oral semaglutide (1.2% mean A1C reduction from baseline) met criteria for noninferiority when compared with liraglutide (1.1% mean A1C reduction from baseline) and met criteria for superiority when compared with placebo (0.2% mean A1C reduction from baseline
In rare situations, there are worries about possible thyroid tumors
Dosage Starting dose: 2.5 mg once weekly (weeks 14) Weeks 58: 5 mg once weekly Weeks 913: 7.5 mg once weekly Weeks 14+: 10 mg (full dose) once weekly Subcutaneous injection in abdomen, thigh or shoulder area
Retrieved 14 June 2025
Mitigating the Risk of Heart Disease People who have diabetes have twice the risk of heart disease
